Recently, Goldman Sachs raised its target price for Bristol-Myers Squibb (BMY) from $51 to $57 while maintaining a “Neutral” rating. The institution believes the company has achieved a prudent balance between risk and reward, with its 4.6% dividend yield and approximately 85% payout ratio providing some cushion even under pressure. This assessment reveals that while the market is focusing on its long-term challenges, it has not overlooked its current financial resilience and shareholder returns.
Patent risks have become a market consensus when analyzing Bristol-Myers Squibb. To address revenue pressure from the expiration of patents on key products, management has actively strengthened its R&D pipeline through a series of strategic acquisitions in recent years. This move aims to diversify risks across more targets and markets. While not a permanent solution, it has indeed fortified the company’s risk-resistant foundation during critical periods, providing deeper strategic resilience through diversification to navigate industry cycles.
Bristol-Myers Squibb focuses on cardiovascular, immunology, and oncology, with its product portfolio clearly divided into “growth” and “traditional” categories. “Growth” drugs, such as the blockbuster cancer drug Opdivo, still enjoy several years of patent protection, while “traditional” products like the anticoagulant Eliquis are already facing or will soon face competitive pressure after patent expiration. Currently, growth drugs are shouldering the responsibility of driving performance. For example, in the third quarter, sales in this segment increased by 18% year-over-year to $6.9 billion, effectively offsetting a 12% decline in traditional products and driving a slight 3% increase in total revenue to $12.2 billion. This highlights the ongoing internal product momentum shift.
Looking ahead to 2026 and beyond, challenges remain severe. In addition to Revlimid, which has already lost patent protection, two other pillars, Eliquis and Opdivo, will also face patent expiration by the end of this decade. In the first nine months of 2025 alone, these two drugs contributed a combined revenue of over $18.4 billion, accounting for more than half of the company’s total revenue. Even before these products confront the patent cliff, pressure on the company’s total revenue has already become evident. To reverse this situation, Bristol-Myers Squibb is actively advancing its transformation plan, including the recently approved new subcutaneous injectable formulation of Opdivo—Opdivo Qvantig. Such innovative formulations aim to enhance patient convenience and represent one of the company’s strategies to maintain the value of its core products and address competition. The company continues to position itself as a global biopharmaceutical enterprise, committed to discovering, developing, and delivering innovative medicines for patients with serious diseases.
